Showing Results for
- Academic Journals (67)
Search Results
- 67
Academic Journals
- 67
-
From:Reactions Weekly (Issue 1318)A 62-year-old man started treatment with oral pramipexole 0.18mg three times daily for Parkinson's disease. A few days later, he developed hiccups which increased over the next days, and mild nausea which persisted for...
-
From:Reactions Weekly (Issue 1311)A 61-year old man developed a compulsive eating habit while receiving pramipexole for Parkinson's disease [dosage and duration of therapy before reaction not stated]; he also had type 2 diabetes mellitus. He described...
-
From:Reactions Weekly (Issue 1322)A man developed nausea and sleepiness, and a woman developed hypomania, during adjunctive treatment with pramipexole [route not stated] for rapid-cycling bipolar I disorder. A third patient had no reported adverse...
-
From:Archives of Neuropsychiatry (Vol. 50, Issue 1) Peer-ReviewedABSTRACT Restless Legs Syndrome (RLS) may be primary or secondary. As a secondary etiological factor, stroke has been rarely reported in the literature. Here, we present the case of a patient with infarctions in the...
-
From:Parkinson's Disease (Vol. 2020) Peer-ReviewedThe rotigotine transdermal patch (RTP) is a dopamine agonist used to treat Parkinson's disease (PD). Some PD patients cannot continue RTP treatment due to application site reactions. We explored sites for RTP where...
-
From:Reactions Weekly[S] A 68-year-old man with a 3-year history of Parkinson's disease, for which he was receiving levodopa, started receiving additional pramipexole [dosage not stated]. Shortly after treatment initiation, he developed...
-
From:CNS Drugs (Vol. 24, Issue 4) Peer-ReviewedPramipexole extended release (ER) is a non-ergolinic dopamine receptor agonist available for use as a once-daily oral treatment for the signs and symptoms of early and advanced idiopathic Parkinson's disease....
-
From:PLoS ONE (Vol. 15, Issue 1) Peer-ReviewedIntroduction Parkinson's disease (PD) patients treated with pramipexole (PPX) and ropinirole (ROP) exhibit a higher risk of developing impulse control disorders (ICDs), including gambling disorder, compulsive shopping,...
-
From:PLoS ONE (Vol. 10, Issue 3) Peer-ReviewedOur recent study has indicated that a moderate lesion of the mesostriatal and mesolimbic pathways in rats, modelling preclinical stages of Parkinson's disease, induces a depressive-like behaviour which is reversed by...
-
From:Reactions Weekly (Issue 1242)An 83-year-old man developed pathological hypersexuality initially during treatment with bromocriptine and later during treatment with pramipexole. The man, who had been receiving levodopa/carbidopa for 8 months for...
-
From:Neuroscience Bulletin (Vol. 33, Issue 5) Peer-ReviewedAuthor(s): Song Li 1 2, Weidong Le 1 2 3 Author Affiliations: (1) 0000 0000 9558 1426, grid.411971.b, Liaoning Provincial Center for Clinical Research on Neurological Diseases, The First Affiliated Hospital, Dalian...
-
From:Reactions Weekly (Issue 1252)Munhoz RP, Fabiani G, Becker N, Teive HAG. Increased frequency and range of sexual behavior in a patient with Parkinson's disease after use of pramipexole: a case report. Journal of Sexual Medicine 6: 1177-1180, No. 4,...
-
From:Reactions Weekly (Issue 1269)A 64-year-old woman with Parkinson's disease (PD) began to exhibit compulsive behaviours after starting treatment with pramipexole. The woman initially received carbidopa/levodopa following diagnosis with Hoehn and...
-
From:Reactions Weekly (Issue 1312)A 59-year-old man was diagnosed with Parkinson's disease (PD) and started receiving pramipexole 2.25 mg/day [route not stated]. After 10 months, his dosage was gradually increased to 3 mg/day. He developed an insatiable...
-
From:Reactions Weekly (Issue 1336)A 60-year-old man experienced a recurrence of cluster headache (CH) after starting pramipexole treatment for restless legs syndrome. The man presented with restless legs syndrome (RLS), which had been ongoing for...
-
From:PLoS ONE (Vol. 16, Issue 6) Peer-ReviewedGambling Disorder (GD) has recently been reclassified from an impulse-control disorder to a behavioural addiction and, as in other addictive disorders, the dopaminergic reward system is involved. According to...
-
From:Expert Review of Neurotherapeutics (Vol. 5, Issue 5) Peer-ReviewedAuthor(s): J Carsten Möller 1 Keywords: daytime sleepiness; depression; pramipexole; resting tremor; valvulopathy Parkinson's disease (PD) is a progressively disabling neurodegenerative disorder. The disease is...
-
From:Formulary (Vol. 43, Issue 4) Peer-ReviewedCefuroxime for oral suspension, 125 and 250 mg/5 mL (equiv to Ceftin for oral suspension) RANBAXY Pramipexole tablets, 0.125, 0.25, 0.5, 1, and 1.5 mg (equiv to Mirapex tablets) BARR Alendronate once-daily...
-
From:Reactions Weekly (Issue 1245)[S] A 21-year-old man developed tardive dyskinesia during treatment with antipsychotics. The man had a history of adjustment disorder with mixed emotional and social disturbance, aggressive behaviour requiring...
-
From:PLoS ONE (Vol. 14, Issue 12) Peer-ReviewedSchizophrenia and Parkinson's disease can be controlled with dopamine antagonists and agonists. In order to improve the understanding of the reaction mechanism of these drugs, in this investigation we present a quantum...